A Study of IBI362 in Participants With Obesity or Overweight

Obesity Or Overweight Clinical Trial

Official title:
A Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of IBI362 in Chinese Participants With Obesity or Overweight (GLORY-1)

Status Active, not recruiting

Clinical Trial Summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study evaluating the efficacy and safety of IBI362 in overweight or obese subjects. Subjects will be randomly assigned to IBI362 low-dose, high-dose and placebo groups. The entire trial cycle includes a 2-week screening period, a 48-week double-blind treatment period, and a 12-week drug withdrawal follow-up period after the end of treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05607680
Study type	Interventional
Source	Innovent Biologics (Suzhou) Co. Ltd.
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	November 19, 2022
Completion date	April 14, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03629301` - Obesity Treatment Using an Internet-delivered Intervention Based on the Diabetes Prevention Program in Mexican Adults	N/A
Completed	`NCT05153590` - A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland
Recruiting	`NCT05996848` - A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight	Phase 3
Recruiting	`NCT05813925` - A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight	Phase 3